Does it excite you to work with cell-based disease models that advance peptide-based medicines for obesity and metabolic health, and do you have experience with in vitro biology, pharmacology and mechanism-of-action studies? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
Your new position
As Principal Scientist – In Vitro Biology & Pharmacology, you will play a central role in driving research projects and advancing biological understanding of peptide-based drug candidates within metabolism and obesity. The position offers a unique opportunity to shape scientific approaches and deepen insight into tissue-specific mechanisms of action. You will work cross-functionally to translate biology into robust preclinical hypotheses and decision-ready data that supports progression of candidates.
We offer exciting responsibilities:
Your profile
You are a collaborative and curious scientist who enjoys staying up to date with disease-relevant science and actively driving scientific discussions with colleagues at all levels. You bring broad knowledge of obesity-related biology and hands-on experience building in vitro disease models to investigate mechanism-of-action questions. You thrive in a dynamic environment, communicate clearly, and are motivated by making a meaningful impact on patient-relevant science.
Qualifications
Your new team
The Department of Molecular Pharmacology is a dynamic and social environment with a strong collaborative spirit and supportive colleagues. The department comprises 12 scientists and 8 laboratory technicians and is organized into two teams. We work closely across the department using a broad range of cellular assays to support the identification, optimization, and mechanistic understanding of our drug candidates. The open position is within our In Vitro Biology group, which focuses on cell-based disease models and biomarker evaluation. Zealand Pharma is a dynamic organization with many opportunities to impact projects across all stages of the pipeline, as well as your own career development and the future of the company.
Let's bond and be bold
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture.
Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold.
Interested in bonding with us? Then please apply no later than June 19, 2026, or as soon as possible. The applications will be reviewed as they come in. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying.
For further information, please contact Head of In Vitro Biology, Gitte Lund Christensen and GLChristensen@zealandpharma.com
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com
#LI-Onsite
At Zealand Pharma, we are a Danish biotechnology company on a mission to change lives with next generation peptide medicines.
In our effort to reach our goals, bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other.
Ten drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market. Our current pipeline of internal product candidates focuses on obesity, chronic inflammation, and certain rare diseases.
Our leading obesity programs are backed by strong partners, including Roche and Boehringer Ingelheim.
We are based in Copenhagen (Søborg), Denmark, with a team in the U.S. For further information about our business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn.
